PSA (total), Ultrasensitive PSA, prostate cancer antigen 3, Prostate Health Index and free PSA%, PSA velocity, 4Kscore.
To assess prostate health and assist in diagnosis of disorders such as prostate cancer, inflammation, and benign hyperplasia and to evaluate effectiveness of medical and surgical therapeutic interventions.
There are no food, fluid, activity, or medication restrictions unless by medical direction.
Method: Electrochemiluminescent Immunoassay.
|Conventional Units||SI Units (Conventional Units × 1)|
|Total PSA assay (for use in initial screening)|
|0–4 ng/mL||0–4 mcg/L|
|Ultrasensitive PSA assay (use in monitoring following radical prostatectomy for recurrence; assay has a much lower detectable limit—sensitivity of some assays is as low as less than 0.01 ng/mL)||Less than 0.05 = absence of residual cancer|
|Prostate Cancer Antigen 3 (PCA3)||Negative = Score less than 25|
|Prostate Health Index (PHI)PHI = p2PSA/(free PSA × total PSA)||PHI less than 27% have a relatively low probability for prostate cancer; PHI between 27% and 55% predict a moderate probability for prostate cancer; and PHI greater than 55% have an increased risk for prostate cancer|
|Some guidelines recommend a lower range for Total PSA: 0–2.5 ng/mL.There is usually no reportable range for free PSA; it is reported as a percentage of the total PSA.|
|Free PSA (%) where Free PSA % = (free PSA/total PSA) × 100||Probability of Developing Prostate Cancer|
|Greater than 30%||8%–20%|
|PSA velocity ng/mL|
|Change of less than 0.75/yr||Low|
|Change of greater than 0.75/yr||Suspicious|
|4K score||Less than or equal to 7.5% = Low Risk for a diagnosis of aggressive prostate cancer (Gleason score 7 or higher) if a prostate biopsy were done|
Critical Findings and Potential Interventions
There's more to see -- the rest of this topic is available only to subscribers.